BMS

Showing 15 posts of 285 posts found.

opdivo_1_1

NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma

July 5, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma

Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …

opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

shutterstock_159488225

New cancer clinical trial model promises to cut costs and development time

May 15, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, Cancer, MD AndersonCancer Center, clinical trials, pharma

Researchers from the University of Texas MD Anderson Cancer Center have been developing and testing a new model for the …

top_ten

Top Ten most popular articles on Pharmafile.com this week

May 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, EMA, Kymriah, Novartis, Porton Biopharma, Regeneron, Roche, Sandoz, Sanofi, Shire, Takeda, biosimilars, dementia

It’s Friday again and it’s been a week busy with companies’ financials. One company’s in particular were of note due …

BMS pulls the plug on Phase 3 trials of IDO1 inhibitor

May 2, 2018
Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …

john_tsai

Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head

April 19, 2018
Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma

Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …

BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer

April 18, 2018
Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

humacao_exterior

BMS restructure will transfer 90 jobs from NY state to Massachusetts and New Jersey

March 15, 2018
Manufacturing and Production BMS, Bristol-Myers Squibb, Massachusetts, New York, new jersey, pharma

Bristol-Myers Squibb has announced plans to relocate around 90 roles from the state of New York to facilities in Massachusetts …

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

Bristol-Myers Squibb’s Yervoy scores EU approval in paediatric melanoma

January 23, 2018
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, EU, Yervoy, pharma

Bristol-Myers Squibb has revealed that its immunotherapy Yervoy (ipilimumab) has received an expanded indication from the European Commission, approving the …

humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

October 13, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

Latest content